Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab and Coronary Flow (CHORAL Flow)
NCT04073134Phase 4Terminated
- Sponsor
- Imperial College London
- Start
- Sep 2019
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of evolocumab in coronary artery disease (CAD), hyperlipidemia, sponsored by Imperial College London. Started Sep 2019; status: terminated.
02
Drugs
evolocumab
03
Conditions
coronary artery disease (CAD)hyperlipidemia
Beyond the preview
Go deeper on NCT04073134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04073134.